Tag Archives: Namdiatream

Namdiatream; a European multimodal diagnostics project

I’ve written about lab-on-a-chip projects, point-of-care diagnostics, and other such initiatives on several occasions, most recently in a Mar. 1, 2013 posting about a technique where powder is used to make the diagnostic device more portable. This time it was a Europe-wide project described in a Mar. 4, 2013 news item on Nanowerk,which caught my attention (Note: A link has been removed),

The plan of the EU-funded consortium Nanotechnological toolkits for multi-modal disease diagnostics and treatment monitoring (Namdiatream) is not to cure cancer, per se, but to boost the sensitivity of diagnostics and the ability to monitor progress during treatment. They focused on three types – breast, prostate and lung cancer.

… The prototype devices being developed during the four-year project will detect common cancer cells much earlier and, with timely treatment, improve the chances of recovery.

According to the project leader, Professor Yuri Volkov of Trinity College Dublin’s School of Medicine, the portable nanodevices are based on innovative lab-on-a-chip, -bead and -wire technologies applicable in different settings – clinical, research, or point of care (i.e. hospitals). These lab-on-x technologies exploit the photo-luminescent (‘glow-in-the-dark’ light emitting), plasmonic (‘light-on-a-wire’), magnetic and unique optical properties of nanomaterials.

Volkov offers some insight into how the project started and its current state of evolution (from the news item),

This is ground-breaking work made possible thanks to advanced technology but also to EU funding for cross-border investigations. Teams across Europe were doing related but fragmented research, suggests Prof. Volkov. This risked leaving a team dangling if their approach failed or lacked funding.

“So we integrated our research and identified joint strengths to help one another develop the best technological approaches in case something didn’t work in one, or synergies were identified, thereby increasing the chances of wider success.”

At its half-way stage, notes Prof. Volkov, Namdiatream underwent a natural evolution when it became clear that by merging and refocusing work in some areas – i.e. in fluorescent nanomaterial technology and magnetic nanowire barcodes – it would speed up industrial implementation efforts.

“Now, work on the preclinical prototype devices is well under way,” he confirms. But one of the many remaining challenges is to calibrate their sensitivity, so that they do not give false readings, for instance.

The Namdiatream (Nanotechnological Toolkits for Multi-Modal Disease Diagnostics and Treatment Monitoring) home page offers more detail about the project,

Namdiatream is a truly interdisciplinary and Pan-european consortium that builds around 7 High-Tech SMEs [small to medium enterprises], 2 Multinational industries and 13 academic institutions. NAMDIATREAM will develop nanotechnology-based toolkit to enable early detection and imaging of molecular biomarkers of the most common cancer types and of cancer metastases, as well as permitting the identification of cells indicative of early-stage disease onset. The project is built on the innovative technology concepts of super-sensitive “lab-on-a-bead”, “lab-on-a-chip” and “lab-on-a-wire” nano-devices.

Interestingly, this too was on the home page,

The ETP Nanomedicine documents point out that nanotechnology has yet to deliver practical solutions for the patients and clinicians in their struggle against common, socially and economically important diseases such as cancer. Therefore NAMDIATREAM results will firstly aim to deliver to the diagnostic and medical imaging device companies involved in the consortium, and the clinical and academic partners. This could further provide the basis for cancer therapeutics as it will be possible to accurately assess the kinetics of cancer cell destruction during the course of appropriate therapy.